IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio develops ex vivo-expanded and activated gamma-delta T cells based upon its deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. IN8bio’s platform employs allogeneic, autologous, and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently the most clinically advanced gamma-delta T cell company and the first company to bring genetically modified gamma-delta T cells into the clinic.
For more information about the Company and its programs, visit www.IN8bio.com.
-
Industry
-
Biotechnology Research
-
Company size
-
11-50 employees
-
Headquarters
-
New York , New York
-
Type
-
Public Company
-
Founded
-
2016
-
Specialties
-
cell therapy, solid tumors, Glioblastoma, Drug Resistant Immunotherapy, gamma delta T cells, hematological tumors, allogeneic, autologous, iPSC, genetically modified gamma delta T cells, and GBM
